KRT17 stabilizes EPN1 via inhibiting SMURF1-mediated ubiquitination to modulate Wnt/β-catenin signaling output and stem-like traits in ovarian cancer

This study reveals that Keratin 17 (KRT17) promotes ovarian cancer progression and chemoresistance by stabilizing EPN1 through the inhibition of SMURF1-mediated ubiquitination, thereby enhancing Wnt/β-catenin signaling and stem-like traits.

The Gist

The Big Picture: A Cellular "Bodyguard" System

Imagine your body is a bustling city, and the cells are the buildings. In a healthy city, there are strict rules about how buildings grow and when they stop. But in Ovarian Cancer, the city is in chaos. Buildings are growing out of control, refusing to die, and becoming impossible to destroy with standard demolition crews (chemotherapy).

This paper discovers a specific "security guard" inside these cancer cells that is helping them break the rules. The researchers found out exactly how this guard works and how to trick it into letting the cancer be destroyed.

---

The Main Characters

1. KRT17 (The Bodyguard): Think of this as a tough, structural protein that usually just holds the cell together (like the steel beams in a building). But in cancer, it has taken on a second job: it's protecting a dangerous signal.
2. EPN1 (The Signal Booster): This is a protein that acts like a megaphone. When it's loud, it shouts orders to the cell to "Grow! Move! Stay alive!"
3. SMURF1 (The Trash Collector): This is a cellular machine designed to find bad proteins, tag them with a "garbage tag" (ubiquitination), and throw them in the trash can (the proteasome) to be destroyed.
4. Wnt/β-catenin (The Construction Crew): This is the ancient signaling pathway that tells cells to build more of themselves. In cancer, this crew never stops working, leading to tumors and "stem-like" cells that are super tough to kill.

---

The Story: How the Cancer Survives

1. The Problem: The Bodyguard is Too Protective

In healthy cells, the "Trash Collector" (SMURF1) finds the "Signal Booster" (EPN1) when it's not needed, tags it, and throws it away. This keeps the "Construction Crew" (Wnt signaling) calm and quiet.

But in ovarian cancer, the Bodyguard (KRT17) is overactive. It grabs onto the Signal Booster (EPN1) and physically blocks the Trash Collector (SMURF1) from getting close.

• The Analogy: Imagine SMURF1 trying to put a "GARBAGE" sticker on EPN1. KRT17 stands in front of EPN1, arms crossed, saying, "No! You can't tag him!"
• The Result: Because the Trash Collector can't do its job, EPN1 doesn't get thrown away. It piles up in the cell.

2. The Consequence: The Megaphone Never Turns Off

Because EPN1 isn't being destroyed, it stays at high levels. It keeps shouting "GROW!" to the cell.

• This turns on the Wnt/β-catenin pathway.
• The cell starts acting like a "Stem Cell" (a master builder that can turn into anything). It grows faster, spreads to other parts of the body (metastasis), and becomes very hard to kill.
• The Analogy: The construction crew is working 24/7, building a massive, unbreakable fortress.

3. The Evidence: What the Researchers Found

The team looked at real ovarian cancer patients and found that:

• Patients with high levels of the Bodyguard (KRT17) had much shorter survival times.
• When they removed the Bodyguard (KRT17) from cancer cells in a lab:
  • The Trash Collector (SMURF1) could finally reach the Signal Booster (EPN1).
  • EPN1 got tagged and destroyed.
  • The "GROW" signal stopped.
  • The cancer cells slowed down, stopped spreading, and started dying.
  • Crucially: The cancer cells became much more sensitive to Cisplatin (a common chemotherapy drug). Without the Bodyguard protecting them, the drugs could finally do their job.

4. The "Magic Bullet" Experiment

To prove this was the only reason, they did a clever trick:

• They removed the Bodyguard (KRT17), which usually kills the cancer's growth.
• BUT, they also gave the cells a "Super Signal Booster" (a mutant version of EPN1 that the Trash Collector cannot tag).
• Result: Even without the Bodyguard, the cancer started growing again! This proved that KRT17's only job in this context was to protect EPN1.

---

Why This Matters (The Takeaway)

This paper solves a mystery: How does a structural protein (KRT17) control complex cancer signals?

It turns out the cell's "skeleton" (cytoskeleton) isn't just for shape; it's also a security system.

• The Bad News: If KRT17 is high, the cancer is aggressive and resistant to drugs.
• The Good News: We now know the exact lock and key. If we can find a way to stop KRT17 from hugging EPN1, or if we can help the Trash Collector (SMURF1) get past the Bodyguard, we might be able to turn off the cancer's growth signal and make chemotherapy work again.

In short: The researchers found that a "bodyguard" protein is protecting a "megaphone" protein from being thrown in the trash. This keeps the cancer loud, aggressive, and drug-resistant. If we can fire the bodyguard, the megaphone gets silenced, and the cancer becomes vulnerable again.

Technical Summary

1. Problem Statement

Ovarian cancer (OC) progression and chemoresistance are driven by dysregulated oncogenic signaling, particularly the Wnt/β-catenin pathway, which governs cancer stem-like traits (self-renewal, plasticity, and tumor initiation). While the role of Wnt/β-catenin in OC is established, the upstream mechanisms linking cytoskeletal reorganization to this signaling pathway remain poorly understood. Specifically, the role of the intermediate filament protein Keratin 17 (KRT17) in regulating oncogenic signaling effectors via post-translational modifications in OC has not been elucidated.

2. Methodology

The study employed a multi-faceted approach combining bioinformatics, molecular biology, and animal models:

• Bioinformatics & Clinical Correlation: Analysis of GEO datasets (GSE66957, GSE140082) and clinical tissue specimens (143 OC patients) to assess KRT17 and EPN1 expression, prognostic significance, and correlation with clinicopathological features.
• Cell Line Models: Utilization of OC cell lines (SK-OV-3, CAOV-3) and normal ovarian epithelial cells (IOSE80).
• Genetic Manipulation:
  • Knockdown: Lentiviral shRNA-mediated silencing of KRT17.
  • Overexpression/Rescue: Lentiviral re-expression of wild-type (WT) EPN1 and a ubiquitination-resistant mutant (EPN1-K107R) in KRT17-depleted cells.
• Molecular Mechanism Investigation:
  • IP-MS: Immunoprecipitation followed by Mass Spectrometry to identify KRT17-interacting proteins.
  • Co-Immunoprecipitation (Co-IP): Validating physical interactions between KRT17, EPN1, and the E3 ligase SMURF1.
  • Ubiquitination Assays: Assessing EPN1 ubiquitination levels using Flag-Ub plasmids and MG132 treatment.
  • Protein Turnover: Cycloheximide (CHX) chase assays to measure protein half-life.
  • Site-Directed Mutagenesis: Creating K107R and K117R mutants to pinpoint the specific ubiquitination site.
• Functional Assays:
  • In vitro: CCK-8 (proliferation), colony formation, Transwell/wound healing (migration), flow cytometry (apoptosis), spheroid formation, and ALDH activity (stemness).
  • In vivo: Xenograft tumor models in nude mice to evaluate tumor growth and drug response.
  • Chemoresistance: Sensitivity assays using cisplatin.
• Statistical Analysis: Kaplan-Meier survival analysis, Spearman correlation, and t-tests/ANOVA.

3. Key Contributions

The study identifies a novel KRT17–EPN1 regulatory axis that links the cytoskeleton to Wnt/β-catenin signaling through a specific ubiquitination mechanism:

1. Discovery of Interaction: KRT17 physically interacts with the endocytic adaptor protein EPN1.
2. Mechanism of Stabilization: KRT17 binding prevents the E3 ubiquitin ligase SMURF1 from associating with EPN1.
3. Site Specificity: SMURF1 targets EPN1 for proteasomal degradation via ubiquitination at Lysine 107 (K107). KRT17 inhibits this specific modification, thereby stabilizing EPN1.
4. Downstream Signaling: Stabilized EPN1 promotes the accumulation of β-catenin and upregulates stemness markers (SOX2, OCT4, NANOG, CD133), driving the Wnt/β-catenin pathway.

4. Key Results

• Clinical Relevance:
  • KRT17 and EPN1 are significantly upregulated in OC tissues compared to normal tissues.
  • High expression of both proteins correlates with advanced tumor stage, metastasis, larger tumor size, and poor overall survival (OS) and disease-free survival (DFS).
• Functional Impact of KRT17:
  • Knockdown: Silencing KRT17 suppressed OC cell proliferation, migration, and clonogenicity while inducing apoptosis.
  • In Vivo: KRT17 depletion significantly reduced tumor volume and weight in xenograft models.
  • Stemness: KRT17 loss decreased ALDH activity and tumorsphere formation capacity.
• Molecular Mechanism:
  • KRT17 depletion led to a rapid decrease in EPN1 protein levels (without affecting mRNA), indicating post-transcriptional regulation.
  • KRT17 loss increased the interaction between SMURF1 and EPN1, leading to increased polyubiquitination of EPN1 at K107.
  • Treatment with the proteasome inhibitor MG132 rescued EPN1 levels in KRT17-depleted cells.
  • Rescue Experiments: Re-introducing wild-type EPN1 partially restored the malignant phenotypes lost by KRT17 knockdown. Crucially, the ubiquitination-resistant mutant (EPN1-K107R) fully rescued proliferation and migration even in the absence of KRT17, confirming that K107 stability is the critical node.
• Signaling and Chemoresistance:
  • The KRT17–EPN1 axis positively regulates Wnt/β-catenin signaling (increased p-GSK3β, β-catenin, and CCND1).
  • KRT17 depletion sensitized OC cells to cisplatin.
  • Re-expression of EPN1 (specifically the K107R mutant) reversed cisplatin sensitivity, suggesting that the chemoresistance phenotype is mediated by EPN1 stability and subsequent stemness activation.

5. Significance

• Novel Mechanism: This study provides the first evidence that an intermediate filament protein (KRT17) acts as a scaffold to regulate the stability of a signaling adaptor (EPN1) by inhibiting E3 ligase-mediated ubiquitination.
• Therapeutic Insight: It elucidates a mechanism for cisplatin resistance in ovarian cancer, linking cytoskeletal dynamics to stemness and drug tolerance via the Wnt/β-catenin pathway.
• Prognostic Value: KRT17 and EPN1 are identified as potential biomarkers for poor prognosis in OC patients.
• Paradigm Shift: The findings challenge the traditional view of keratins as mere structural components, highlighting their active role in orchestrating oncogenic signaling networks through post-translational regulation.

Conclusion: The KRT17–EPN1 axis represents a critical regulatory node in ovarian cancer. KRT17 stabilizes EPN1 by blocking SMURF1-mediated ubiquitination at K107, thereby sustaining Wnt/β-catenin signaling, promoting cancer stemness, and driving chemoresistance. Targeting this axis or the K107 ubiquitination site could offer new therapeutic strategies for overcoming chemoresistance in ovarian cancer.